Search

Vir Biotechnology Inc

Geschlossen

BrancheGesundheitswesen

9.19 2.22

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.92

Max

9.19

Schlüsselkennzahlen

By Trading Economics

Einkommen

80M

-46M

Verkäufe

239M

239M

EPS

0.47

Gewinnspanne

-19.09

Angestellte

367

EBITDA

201M

78M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+136.56% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.3M

1.5B

Vorheriger Eröffnungskurs

6.97

Vorheriger Schlusskurs

9.19

Nachrichtenstimmung

By Acuity

20%

80%

46 / 340 Ranking in Healthcare

Vir Biotechnology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2026, 19:36 UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

10. Aug. 2026, 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

7. Aug. 2026, 19:36 UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

6. Aug. 2026, 23:21 UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

5. Aug. 2026, 23:41 UTC

News
Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

3. Aug. 2026, 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

30. Juli 2026, 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

29. Juli 2026, 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

28. Juli 2026, 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27. Juli 2026, 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25. Juli 2026, 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24. Juli 2026, 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21. Juli 2026, 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20. Juli 2026, 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Peer-Vergleich

Kursveränderung

Vir Biotechnology Inc Prognose

Kursziel

By TipRanks

136.56% Vorteil

12-Monats-Prognose

Durchschnitt 21.29 USD  136.56%

Hoch 30 USD

Tief 15 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vir Biotechnology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

8

Buy

0

Halten

0

Sell

Stimmung

By Acuity

46 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
help-icon Live chat